SG158141A1 - Pancreatic polypeptide family motifs, polypeptides and methods comprising the same - Google Patents

Pancreatic polypeptide family motifs, polypeptides and methods comprising the same

Info

Publication number
SG158141A1
SG158141A1 SG200908344-5A SG2009083445A SG158141A1 SG 158141 A1 SG158141 A1 SG 158141A1 SG 2009083445 A SG2009083445 A SG 2009083445A SG 158141 A1 SG158141 A1 SG 158141A1
Authority
SG
Singapore
Prior art keywords
polypeptides
methods
same
pancreatic polypeptide
polypeptide family
Prior art date
Application number
SG200908344-5A
Other languages
English (en)
Inventor
Odile Esther Levy
Carolyn M Jodka
Soumitra S Ghosh
David Parkes
Richard A Pittner
Lawrence J Daesouza
John S Ahn
Kathryn S Prickett
Jonathan David Roth
Sean H Adams
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/004351 external-priority patent/WO2005077094A2/en
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of SG158141A1 publication Critical patent/SG158141A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG200908344-5A 2004-12-13 2005-12-12 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same SG158141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63589704P 2004-12-13 2004-12-13
PCT/US2005/004351 WO2005077094A2 (en) 2004-02-11 2005-02-11 Pancreatic polypeptide family motifs and polypeptides comprising the same
US11/055,098 US8603969B2 (en) 2004-02-11 2005-02-11 Pancreatic polypeptide family motifs and polypeptides comprising the same

Publications (1)

Publication Number Publication Date
SG158141A1 true SG158141A1 (en) 2010-01-29

Family

ID=38261573

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200908344-5A SG158141A1 (en) 2004-12-13 2005-12-12 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same

Country Status (12)

Country Link
EP (3) EP1824876B1 (ja)
JP (1) JP5743371B2 (ja)
KR (1) KR101272402B1 (ja)
AU (1) AU2005316524B2 (ja)
BR (1) BRPI0518559A2 (ja)
CA (2) CA2588594C (ja)
IL (1) IL183405A (ja)
MX (1) MX2007006830A (ja)
NZ (1) NZ555533A (ja)
PL (1) PL1824876T3 (ja)
SG (1) SG158141A1 (ja)
WO (1) WO2006066024A2 (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114958B2 (en) 2004-02-11 2012-02-14 Amylin Pharmaceuticals, Inc. Amylin family peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
AU2005211776B2 (en) 2004-02-11 2012-02-02 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2173773A4 (en) 2007-07-06 2010-07-07 Theratechnologies Inc BIFUNCTIONAL FUSION PROTEINS OF ALPHA-MELANOCYTE STIMULATION HORMONE (ALPHA-MSH) AND AURICULAR NATRIURETIC PROTEIN (ANP), AND USES THEREOF IN HYPERTENSION AND ACUTE RENAL INJURY
GB0817067D0 (en) * 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
JP5767582B2 (ja) 2009-07-02 2015-08-19 武田薬品工業株式会社 ペプチド及びその用途
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB201101459D0 (en) * 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
UY35548A (es) * 2013-05-02 2014-11-28 Glaxosmithkline Ip No 2 Ltd Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN110741015B (zh) * 2017-05-16 2023-08-25 芝加哥大学 用于治疗和/或预防致病性真菌感染和维持微生物群系共生的组合物和方法
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂
CA3175725A1 (en) 2020-04-17 2021-10-21 William Blackwell Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use
EP4192853A1 (en) 2020-08-07 2023-06-14 Boehringer Ingelheim International GmbH Soluble npy2 receptor agonists

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011A (en) * 1845-04-26 Lock fob
US1696901A (en) 1925-11-30 1929-01-01 Visuola Corp Musical instructing and directing equipment
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4891357A (en) 1985-02-11 1990-01-02 University Of Florida Methods and compositions for stimulation of appetite
DE68929566D1 (de) 1988-05-13 2010-01-28 Amgen Inc Verfahren zur Isolierung und Reinigung von G-CSF
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
JPH02225497A (ja) * 1989-02-27 1990-09-07 Suntory Ltd ブタ上部小腸由来ペプチドのｎ端部アナログペプチド
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
EP0692971A4 (en) 1993-03-29 1997-11-12 Univ Cincinnati PEPTIDE YY ANALOGS AND USES THEREOF
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5912227A (en) 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
JP2000510164A (ja) 1997-02-14 2000-08-08 バイエル・コーポレーシヨン 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体
PT1019077E (pt) 1997-08-08 2008-02-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
JP3036480B2 (ja) 1997-08-25 2000-04-24 日本電気株式会社 バーコード読取装置およびその焦点制御方法
BR9814189A (pt) 1997-11-14 2000-10-03 Amylin Pharmaceuticals Inc "compostos agonistas da exendina"
EP1066314B1 (en) 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6013622A (en) 1998-04-15 2000-01-11 Nutriceutical Technology Corporation Method of regulating appetite and metabolism
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US6734166B1 (en) 2000-02-08 2004-05-11 North Carolina State University Method of reducing aluminum levels in the central nervous system
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
ATE450269T1 (de) 2000-12-14 2009-12-15 Amylin Pharmaceuticals Inc Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
CA2472882A1 (en) * 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
WO2003105763A2 (en) 2002-06-14 2003-12-24 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
US20070027073A1 (en) * 2003-04-08 2007-02-01 Menachem Rubinstein Long-acting derivatives of pyy agonists
AU2005211776B2 (en) * 2004-02-11 2012-02-02 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same

Also Published As

Publication number Publication date
WO2006066024A8 (en) 2007-07-19
CA2588594A1 (en) 2006-06-22
AU2005316524A1 (en) 2006-06-22
CA2836267C (en) 2016-06-21
JP5743371B2 (ja) 2015-07-01
EP3000826A1 (en) 2016-03-30
IL183405A0 (en) 2007-09-20
NZ555533A (en) 2010-03-26
CA2836267A1 (en) 2006-06-22
EP2360180A2 (en) 2011-08-24
AU2005316524B2 (en) 2012-01-12
EP1824876B1 (en) 2015-07-29
EP2360180A3 (en) 2012-02-08
PL1824876T3 (pl) 2016-01-29
CA2588594C (en) 2014-02-18
KR101272402B1 (ko) 2013-06-10
KR20070091652A (ko) 2007-09-11
EP1824876A2 (en) 2007-08-29
MX2007006830A (es) 2008-02-07
JP2008534435A (ja) 2008-08-28
IL183405A (en) 2012-02-29
BRPI0518559A2 (pt) 2008-11-25
WO2006066024A2 (en) 2006-06-22
WO2006066024A3 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
GB0700909D0 (en) Novel antigen-binding polypeptides and their uses
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
EP1578930A4 (en) CNGH0004 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
DE60120712D1 (en) Kallikrein gen
WO2004087874A3 (en) Novel nucleic acids and polypeptides
TW200630348A (en) Tadalafil crystal forms and processes for preparing them
WO2006063028A3 (en) Immunostimulatory compositions and uses thereof
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
TW200510398A (en) Novel compounds
EP1539792A4 (en) CNGH0005 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
EP2292666A3 (en) Neoplasm specific antibodies and uses thereof
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
WO2004005351A3 (en) Neoplasm specific antibodies and uses thereof
HK1223113A1 (zh) 胰多肽族基序、多肽和包括它們的方法
EP1545575A4 (en) POLYPEPTIDES OF P. ARIASI POLYPEPTIDES P. PERNICIOSUS AND METHODS OF USE
WO2000073345A3 (en) Antibodies specific for mycobacterial polypeptides and uses thereof
WO2003099783A3 (en) Tropane compounds
TW200504218A (en) Methods for preventing gluconoylation of proteins
EP1392340A4 (en) CYTOTOXIC PEPTIDES, PEPTIDOMIMETICS BASED ON THESE PEPTIDES, AND METHODS OF USE